Send me real-time posts from this site at my email

Feb. 25 - Trading List: Updates, Analyst Actions, Our Take - EPZM

Notable updates, news, or analysts actions from our trading lists followed by 'Our Take'.

Epizyme downgraded to Equal Weight on Tazverik challenges at Morgan Stanley

Morgan Stanley analyst David Lebowitz downgraded Epizyme to Equal Weight from Overweight with a price target of $14, down from $27, following Q4 results that he said illustrate how the pandemic continues to weigh on the launch of Tazverik for the treatment of follicular lymphoma, or FL. He expects 2021 to continue to be a challenging launch environment, leading him to lower his Tazverik sales expectations and downgrade the stock, Lebowitz tells investors in a research note.

Our Take:  "We still like Epizyme, although a bit more patience is needed. We would use the weakness to add to positions by selling naked/cash backed puts."

$EPZM, Epizyme, Inc. / H1

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so)!

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page.


Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue